Conference Dates: Dec 03-04, 2009
Washington DC[edit Location]
Is The Next Golden Age for BioPharma Almost Here?
Conventional wisdom says these are down times for BioPharma companies. Dry pipelines, increased regulation, and payment cuts are part of the reality of today’s playing field. It may just be the opposite. Increased regulation makes for a more confident regulator that can make bolder decisions. In turn, that could precipitate innovation in areas once thought to be no-fly zones for innovative companies. And while payment cuts may prove to be collateral damage resulting from health reform, the industry will have an influx of new customers like it has never seen before.
At the FDA/CMS Summit, find out why 2010 may be the start of another Golden Age for BioPharma companies. New Products. New Customers, and New Marketing.
Health Care Reform: What’s Next?
Hear from leaders in government and industry about how health care reform will affect your business, How will development programs have to change to satisfy demands for comparative research? What pricing and reimbursement models will best position you for success? And where are the real opportunities for growth as the US healthcare market continues to evolve?
[edit description]Click here to register.[edit ]